SUBOXONE (buprenorphine And Naloxone) Sublingual Tablets

2.5Clinical SupervisionTreatment should be initiated with supervised administration, progressing to unsupervised administration asthe patient’s clinical stability permits. SUBOXONE sublingual tablet is subject to diversion and abuse. Whendetermining the prescription quantity for unsupervised administration, consider the patient’s level of stability,the security of his or her home situation, and other factors likely to affect the ability to manage supplies oftake-home medication.Ideally patients should be seen at reasonable intervals (e.g., at least weekly during the first month oftreatment) based upon the individual circumstances of the patient. Medication should be prescribed inconsideration of the frequency of visits. Provision of multiple refills is not advised early in treatment or withoutappropriate patient follow-up visits. Periodic assessment is necessary to determine compliance with the dosingregimen, effectiveness of the treatment plan, and overall patient progress.Once a stable dosage has been achieved and patient assessment (e.g., urine drug screening) does not indicateillicit drug use, less frequent follow-up visits may be appropriate. A once-monthly visit schedule may bereasonable for patients on a stable dosage of medication who are making progress toward their treatmentobjectives. Continuation or modification of pharmacotherapy should be based on the healthcare provider’sevaluation of treatment outcomes and objectives such as:1. Absence of medication toxicity2. Absence of medical or behavioral adverse effects3. Responsible handling of medications by the patient4. Patient’s compliance with all elements of the treatment plan (including recovery-oriented activities,psychotherapy, and/or other psychosocial modalities)5. Abstinence from illicit drug use (including problematic alcohol and/or benzodiazepine use)If treatment goals are not being achieved, the healthcare provider should re-evaluate the appropriateness ofcontinuing the current treatment.2.6Unstable PatientsHealthcare providers will need to decide when they cannot appropriately provide further management forparticular patients. For example, some patients may be abusing or dependent on various drugs, orunresponsive to psychosocial intervention such that the healthcare provider does not feel that he/she has theexpertise to manage the patient. In such cases, the healthcare provider may want to assess whether to referthe patient to a specialist or more intensive behavioral treatment environment. Decisions should be based on atreatment plan established and agreed upon with the patient at the beginning of treatment.Patients who continue to misuse, abuse, or divert buprenorphine products or other opioids should be providedwith, or referred to, more intensive and structured treatment.2.7Discontinuing TreatmentThe decision to discontinue therapy with SUBOXONE sublingual tablets after a period of maintenance shouldbe made as part of a comprehensive treatment plan. Advise patients of the potential to relapse to illicit drug usefollowing discontinuation of opioid agonist/partial agonist medication-assisted treatment. Taper patients toreduce the occurrence of withdrawal signs and symptoms [see Warnings and Precautions (5.7)].2.8Switching between SUBOXONE Sublingual Film and SUBOXONE Sublingual TabletsPatients being switched between SUBOXONE sublingual tablets and SUBOXONE sublingual film should bestarted on the same dosage as the previously administered product. However, dosage adjustments may benecessary when switching between products. Because of the potentially greater relative bioavailability ofSUBOXONE sublingual film compared to SUBOXONE sublingual tablets, patients switching from SUBOXONEReference ID: 4514226

sublingual tablets to SUBOXONE sublingual film should be monitored for over-medication. Those switchingfrom SUBOXONE sublingual film to SUBOXONE sublingual tablets should be monitored for withdrawal or otherindications of under dosing. In clinical studies, pharmacokinetics of SUBOXONE sublingual film was similar tothe respective dosage strengths of SUBOXONE sublingual tablets, although not all doses and dose combinationsmet bioequivalence criteria.3DOSAGE FORMS AND STRENGTHSSUBOXONE sublingual tablet is supplied as an uncoated hexagonal orange tablet in two dosage strengths: Buprenorphine 2 mg/naloxone 0.5 mg, and Buprenorphine 8 mg/naloxone 2 mg4CONTRAINDICATIONSSUBOXONE sublingual tablet is contraindicated in patients with a history of hypersensitivity to buprenorphineor naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see Warnings andPrecautions (5.9)].5WARNINGS AND PRECAUTIONS5.1Addiction, Abuse, and MisuseSUBOXONE sublingual tablets contain buprenorphine, a schedule III controlled substance that can be abused ina manner similar to other opioids, legal or illicit. Prescribe and dispense buprenorphine with appropriateprecautions to minimize risk of misuse, abuse, or diversion, and ensure appropriate protection from theft,including in the home. Clinical monitoring appropriate to the patient’s level of stability is essential. Multiplerefills should not be prescribed early in treatment or without appropriate patient follow-up visits [see DrugAbuse and Dependence (9.2)].5.2Risk Life-Threatening of Respiratory and Central Nervous System (CNS) DepressionBuprenorphine has been associated with life-threatening respiratory depression and death. Many, but not all,post-marketing reports regarding coma and death involved misuse by self-injection or were associated with theconcomitant use of buprenorphine and benzodiazepines or other CNS depressant, including alcohol. Warnpatients of the potential danger of self-administration of benzodiazepines or other CNS depressants whileunder treatment with SUBOXONE sublingual tablets [see Warnings and Precautions (5.3), Drug Interactions(7)].Use SUBOXONE sublingual tablets with caution in patients with compromised respiratory function (e.g., chronicobstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression).Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-relatedhypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present withCSA, consider decreasing the opioid dosage using best practices for opioid taper [see Dosage andAdministration (2.7)].5.3Managing Risks from Concomitant Use of Benzodiazepine or Other CNS DepressantsConcomitant use of buprenorphine and benzodiazepines or other CNS depressants increases the risk of adversereactions including overdose and death. Medication-assisted treatment of opioid use disorder, however,should not be categorically denied to patients taking these drugs. Prohibiting or creating barriers to treatmentcan pose an even greater risk of morbidity and mortality due to the opioid use disorder alone.As a routine part of orientation to buprenorphine treatment, educate patients about the risks of concomitantuse of benzodiazepines, sedatives, opioid analgesics, and alcohol.Reference ID: 4514226

Develop strategies to manage use of prescribed or illicit benzodiazepines or other CNS depressants at initiationof buprenorphine treatment, or if it emerges as a concern during treatment. Adjustments to inductionprocedures and additional monitoring may be required. There is no evidence to support dose limitations orarbitrary caps of buprenorphine as a strategy to address benzodiazepine use in buprenorphine-treatedpatients. However, if a patient is sedated at the time of buprenorphine dosing, delay or omit thebuprenorphine dose if appropriate.Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In somecases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patientoff of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may beappropriate.For patients in buprenorphine treatment, benzodiazepines are not the treatment of choice for anxiety orinsomnia. Before co-prescribing benzodiazepines, ensure that patients are appropriately diagnosed andconsider alternative medications and non-pharmacologic treatments to address anxiety or insomnia. Ensurethat other healthcare providers prescribing benzodiazepines or other CNS depressants are aware of thepatient’s buprenorphine treatment and coordinate care to minimize the risks associated with concomitant use.In addition, take measures to confirm that patients are taking their medications as prescribed and are notdiverting or supplementing with illicit drugs. Toxicology screening should test for prescribed and illicitbenzodiazepines [see Drug Interactions (7)].5.4Unintentional Pediatric ExposureBuprenorphine can cause severe, possibly fatal, respiratory depression in children who are accidentallyexposed to it. Store buprenorphine-containing medications safely out of the sight and reach of children anddestroy any unused medication appropriately [see Patient Counseling Information (17)].5.5Neonatal Opioid Withdrawal SyndromeNeonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use ofopioids during pregnancy, whether that use is medically-authorized or illicit. Unlike opioid withdrawalsyndrome in adults, NOWS may be life-threatening if not recognized and treated in the neonate. Healthcareprofessionals should observe newborns for signs of NOWS and manage accordingly [see Use in SpecificPopulations (8.1)].Advise pregnant women receiving opioid addiction treatment with SUBOXONE sublingual tablet of the risk ofneonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Use inSpecific Populations (8.1)]. This risk must be balanced against the risk of untreated opioid addiction which oftenresults in continued or relapsing illicit opioid use and is associated with poor pregnancy outcomes. Therefore,prescribers should discuss the importance and benefits of management of opioid addiction throughoutpregnancy.5.6Adrenal InsufficiencyCases of adrenal insufficiency have been reported with opioid use, more often following greater than onemonth of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs includingnausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency issuspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency isdiagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid toallow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Otheropioids may be tried as some cases reported use of a different opioid without recurrence of adrenalinsufficiency. The information available does not identify any particular opioids as being more likely to beassociated with adrenal insufficiency.Reference ID: 4514226

5.7Risk of Opioid Withdrawal with Abrupt DiscontinuationBuprenorphine is a partial agonist at the mu-opioid receptor and chronic administration produces physicaldependence of the opioid-type, characterized by withdrawal signs and symptoms upon abrupt discontinuationor rapid taper. The withdrawal syndrome is typically milder than seen with full agonists and may be delayed inonset [see Drug Abuse and Dependence (9.3)]. When discontinuing SUBOXONE sublingual tablet, graduallytaper the dosage [see Dosage and Administration (2.7)].5.8Risk of Hepatitis, Hepatic EventsCases of cytolytic hepatitis and hepatitis with jaundice have been observed in individuals receivingbuprenorphine in clinical trials and through post-marketing adverse event reports. The spectrum ofabnormalities ranges from transient asymptomatic elevations in hepatic transaminases to case reports ofdeath, hepatic failure, hepatic necrosis, hepatorenal syndrome, and hepatic encephalopathy. In many cases,the presence of pre-existing liver enzyme abnormalities, infection with hepatitis B or hepatitis C virus,concomitant usage of other potentially hepatotoxic drugs, and ongoing injecting drug use may have played acausative or contributory role. In other cases, insufficient data were available to determine the etiology of theabnormality. Withdrawal of buprenorphine has resulted in amelioration of acute hepatitis in some cases;however, in other cases no dose reduction was necessary. The possibility exists that buprenorphine had acausative or contributory role in the development of the hepatic abnormality in some cases. Liver functiontests, prior to initiation of treatment is recommended to establish a baseline. Periodic monitoring of liverfunction during treatment is also recommended. A biological and etiological evaluation is recommended whena hepatic event is suspected. Depending on the case, SUBOXONE sublingual tablet may need to be carefullydiscontinued to prevent withdrawal signs and symptoms and a return by the patient to illicit drug use, andstrict monitoring of the patient should be initiated.5.9Hypersensitivity ReactionsCases of hypersensitivity to buprenorphine and naloxone containing products have been reported both inclinical trials and in the post-marketing experience. Cases of bronchospasm, angioneurotic edema, andanaphylactic shock have been reported. The most common signs and symptoms include rashes, hives, andpruritus. A history of hypersensitivity to buprenorphine or naloxone is a contraindication to the use ofSUBOXONE sublingual tablet.5.10Precipitation of Opioid Withdrawal Signs and SymptomsBecause it contains naloxone, SUBOXONE sublingual tablet is highly likely to produce marked and intensewithdrawal signs and symptoms if misused parenterally by individual dependent on full opioid agonists such asheroin, morphine, or methadone. Because of the partial agonist properties of buprenorphine, SUBOXONEsublingual tablet may precipitate opioid withdrawal signs and symptoms in such persons if administeredsublingually before the agonist effects of the opioid have subsided.5.11Risk of Overdose in Opioid Naïve PatientsThere have been reported deaths of opioid naïve individuals who received a 2 mg dose of buprenorphine as asublingual tablet for analgesia. SUBOXONE sublingual tablet is not appropriate as an analgesic.5.12Use in Patients with Impaired Hepatic FunctionBuprenorphine/naloxone products are not recommended in patients with severe hepatic impairment and maynot be appropriate for patients with moderate hepatic impairment. The doses of buprenorphine and naloxonein this fixed-dose combination product cannot be individually titrated, and hepatic impairment results in areduced clearance of naloxone to a much greater extent than buprenorphine. Therefore, patients with severehepatic impairment will be exposed to substantially higher levels of naloxone than patients with normalhepatic function. This may result in an increased risk of precipitated withdrawal at the beginning of treatment(induction) and may interfere with buprenorphine’s efficacy throughout treatment. In patients with moderateReference ID: 4514226

hepatic impairment, the differential reduction of naloxone clearance compared to buprenorphine clearance isnot as great as in subjects with severe hepatic impairment. However, buprenorphine/naloxone products arenot recommended for initiation of treatment (induction) in patients with moderate hepatic impairment due tothe increased risk of precipitated withdrawal. Buprenorphine/naloxone products may be used with caution formaintenance treatment in patients with moderate hepatic impairment who have initiated treatment on abuprenorphine product without naloxone. However, patients should be carefully monitored and considerationgiven to the possibility of naloxone interfering with buprenorphine’s efficacy [see Use in Specific Populations(8.6)].5.13Impairment of Ability to Drive or Operate MachinerySUBOXONE sublingual tablet may impair the mental or physical abilities required for the performance ofpotentially dangerous tasks such as driving a car or operating machinery, especially during treatment inductionand dose adjustment. Caution patients about driving or operating hazardous machinery until they arereasonably certain that SUBOXONE sublingual tablet therapy does not adversely affect his or her ability toengage in such activities.5.14Orthostatic HypotensionLike other opioids, SUBOXONE sublingual tablets may produce orthostatic hypotension in ambulatory patients.5.15Elevation of Cerebrospinal Fluid PressureBuprenorphine, like other opioids, may elevate cerebrospinal fluid pressure and should be used with caution inpatients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may beincreased. Buprenorphine can produce miosis and changes in the level of consciousness that may interferewith patient evaluation.5.16Elevation of Intracholedochal PressureBuprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should beadministered with caution to patients with dysfunction of the biliary tract.5.17Effects in Acute Abdominal ConditionsAs with other opioids, buprenorphine may obscure the diagnosis or clinical course of patients with acuteabdominal conditions.6ADVERSE REACTIONSThe following serious adverse reactions are described elsewhere in the labeling: 6.1Addiction, Abuse, and Misuse [see Warnings and Precautions (5.1)]Respiratory and CNS Depression [see Warnings and Precautions (5.2, 5.3)]Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions (5.5)]Adrenal Insufficiency [see Warnings and Precautions (5.6)]Opioid Withdrawal [see Warnings and Precautions (5.7, 5.10)]Hepatitis, Hepatic Events [see Warnings and Precautions (5.8)]Hypersensitivity Reactions [see Warnings and Precautions (5.9)]Orthostatic Hypotension [see Warnings and Precautions (5.14)]Elevation of Cerebrospinal Fluid Pressure [see Warnings and Precautions (5.15)]Elevation of Intracholedochal Pressure [see Warnings and Precautions (5.16)]Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in theclinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may notreflect the rates observed in practice.Reference ID: 4514226

The safety of SUBOXONE sublingual tabl

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SUBOXONE sublingual tablet safely and effectively. See full prescribing information for SUBOXONE sublingual tablets. SUBOXONE (buprenorphine and naloxone) sublingual tablets for sublingual administration CIII . Initial U.S. Approval: 2002